Leucine tripeptide

Leucine Tripeptide

1. Identity: Chemical and Botanical Nomenclature, Natural Sources, and Common Forms

1.1 Nomenclature and Chemical Identity

The term leucine tripeptide refers to any short-chain peptide containing three amino acid residues, at least one of which is leucine (L-leucine, the proteinogenic form). In the narrowest and most precisely studied sense, trileucine — systematically named L-leucyl-L-leucyl-L-leucine or Leu-Leu-Leu — is the homotripeptide composed exclusively of three L-leucine residues. Trileucine (Leu-Leu-Leu) is a tripeptide formed from three L-leucine residues and has a role as a metabolite. Its molecular formula is C₁₈H₃₅N₃O₄ (PubChem CID 82546), and its systematic IUPAC name is (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoic acid.

As a field, however, leucine-containing tripeptides encompasses a broad family of biologically active, food-derived small peptides in which leucine appears at the N-terminal, C-terminal, or internal position. Well-characterized examples include Leu-Leu-Tyr (LLY), a casein-derived ACE-inhibitory tripeptide, and Gly-Gly-Leu (Diapin), a glycine-dominant tripeptide containing leucine at its C-terminus. The ACE-inhibitory peptide isolated from casein hydrolysate with the amino acid sequence Leu–Leu–Tyr (LLY) exhibits high ACE-inhibitory activity and stability, which holds significant implications for biochemistry and pharmaceutical applications. It has also been reported that the tripeptide glycine-glycine-leucine (Diapin) elevated plasma insulin and GLP-1 levels in diabetic mice.

Dileucine is designated N-L-Leucyl-L-leucine, while trileucine is N-L-Leucyl-L-leucine-L-leucine. The "leucine tripeptide" discussed in this article as a supplement ingredient most commonly refers to either purified trileucine (Leu-Leu-Leu), or leucine-enriched tripeptide fractions released enzymatically from dietary proteins, including whey, casein, soy, and other high-protein food matrices.

1.2 The Parent Amino Acid: L-Leucine

To understand leucine tripeptide, the properties of its constituent building block are foundational. Leucine is a branched-chain α-amino acid and a standard proteinogenic amino acid. Leucine, isoleucine, and valine — the branched-chain amino acids (BCAAs) — are essential amino acids that are potent nutritional signaling molecules for regulating protein synthesis and are not synthesized in mammals. The molecular formula of leucine is C₆H₁₃NO₂.

L-leucine is the natural proteinogenic form; D-leucine is its enantiomer; and DL-leucine is a racemic mixture. Only the L-stereoisomer appears in mammalian protein and can be degraded into simpler compounds by the body's enzymes. The tripeptide Leu-Leu-Leu is therefore composed exclusively of L-leucine residues under physiological conditions, connected by two amide (peptide) bonds.

1.3 Natural Sources of Leucine and Leucine-Containing Tripeptides

Free leucine is found in high concentrations in most dietary proteins. Leucine is present in large proportions — approximately 15% — in hemoglobin, and is one of several essential amino acids for humans, who cannot synthesize it and therefore require dietary sources. Leucine-containing di- and tripeptides are generated naturally during the gastrointestinal digestion of intact proteins: dietary proteins are cleaved within the intestinal lumen to oligopeptides, which are further processed to small peptides (di- and tripeptides) and free amino acids, with the proton-coupled uptake of the more than 8,000 different di- and tripeptides performed by the high-capacity/low-affinity peptide transporter isoform PEPT1 (SLC15A1).

Most high-quality food proteins that strongly stimulate postprandial muscle protein synthesis rates are high in leucine by total amino acid content. Animal-based proteins — including whey (approximately 10–13% leucine by amino acid content), casein, egg albumin, and muscle meats — are particularly rich sources. Animal-based proteins are the best dietary source of leucine dipeptides and by extension leucine-containing small peptides. Plant proteins such as soy, wheat, and pea contain leucine, though typically at lower concentrations and with differing tripeptide profiles upon hydrolysis.

In plants and microorganisms, leucine is synthesized from pyruvic acid, a product of the breakdown of carbohydrates. L-leucine is commonly produced through microbial fermentation for commercial purposes, while derivatives and non-natural analogs may be prepared through chemical synthesis, enzymatic synthesis, resolution, or derivatization routes.

1.4 Commercial Forms and Preparations

Leucine-containing tripeptides are available in several preparatory forms:

• Enzymatic protein hydrolysates: Whey, casein, soy, and fish protein hydrolysates produced by enzymatic digestion that yield a mixture of di- and tripeptide fractions enriched in leucine-containing sequences.
• Isolated/purified trileucine (Leu-Leu-Leu): Synthesized by solid-phase peptide synthesis or produced enzymatically, available as a research compound and emerging supplement ingredient (PubChem CID 82546).
• Dileucine (Leu-Leu, the dipeptide precursor): Commercially formulated as L-leucyl-L-leucine monohydrate; there is evidence suggesting the potential of di- and tripeptides to avoid cytosolic hydrolysis, thereby allowing intact transport across the basolateral membrane.
• Leucine-enriched amino acid blends: Formulations combining free leucine with dileucine and other essential amino acids, such as the DIEAA formula (2 g dileucine, 1 g leucine, 9.15 g total EAA), as tested in clinical studies.

2. Discovery and Historical Context

Leucine itself — the monomeric amino acid that forms the tripeptide — has one of the longest research histories among amino acids. Leucine was isolated from cheese in 1819 and from muscle and wool in its crystalline state in 1820; in 1891 it was synthesized in the laboratory. The first BCAA, leucine, was discovered by a French scientist from cheese in 1819 named Proust; in 1820, Braconnot was the first to use acid hydrolysis to isolate leucine from skeletal muscle and wool; and Schulze synthesized leucine from isovaleraldehyde in 1935.

The biological significance of leucine-containing short-chain peptides, as distinct from the free amino acid, was not investigated in earnest until the late twentieth and early twenty-first centuries, when advances in peptide chemistry, mass spectrometry, and cell biology made it possible to isolate, identify, and measure specific di- and tripeptide species from food hydrolysates and from plasma. The ACE-inhibitory properties of leucine-containing peptides from food proteins — particularly dairy — became an active research area from the 1980s onward. The specific anabolic signaling properties of leucine-containing di- and tripeptides, as compared with free leucine, became the subject of human clinical investigation primarily from the 2010s onward. There is no documented history of leucine tripeptide as an isolated, identified traditional herbal or folk preparation; rather, its history is inseparable from the dietary consumption of protein-rich foods — milk, meat, legumes, and fermented protein products — throughout human history.

3. Key Constituents, Active Compounds, and Mechanisms of Action

3.1 Structural and Chemical Characteristics

Leucine tripeptide (Leu-Leu-Leu) is a small, hydrophobic peptide. Bioactive di/tripeptides are among the most efficient structural units that can cross the intestinal barrier and reach the circulation, owing to their small molecular size and compact conformation. Evidence indicates that more than 70% of protein digestion products in the gastrointestinal tract are absorbed in the form of di/tripeptides, primarily via a specialized proton-coupled transport system.

3.2 Intestinal Absorption: The PepT1 Transporter System

The primary route by which leucine tripeptide (and other di/tripeptides) enters systemic circulation is via the intestinal peptide transporter PEPT1 (SLC15A1). PEPT1 is a high-capacity, low-affinity peptide transporter that mediates the uptake of di- and tripeptides in the intestine and kidney. As a high-capacity, low-affinity, sodium-independent cotransporter, PEPT1 catalyzes the electrogenic uphill transport of L-enantiomers of di- and tripeptides in a sequence-independent manner; peptide translocation is coupled with the movement of H⁺, and the transmembrane electrochemical proton gradient provides the driving force.

PEPT1 is expressed throughout the small intestine, and the capacity of this transporter for the absorption of dipeptides and tripeptides is very high. Crucially, bioactive di/tripeptides have become key components in functional foods due to their excellent bioactivity and absorption properties; however, their oral bioavailability is limited by the complexity of intestinal absorption processes, primarily relying on oligopeptide transporter 1 (PepT1) for transmembrane transport.

A key mechanistic advantage proposed for leucine in tripeptide form over free leucine is the speed and mode of entry: it has been demonstrated that plasma leucine and BCAA-containing dipeptide, such as leucine-leucine, concentrations rapidly increase above baseline after the ingestion of protein hydrolysates compared with intact, nonhydrolyzed protein in young adults. Additionally, there is evidence suggesting the potential of di- and tripeptides to avoid cytosolic hydrolysis, thereby allowing intact transport across the basolateral membrane. This intact transport may allow leucine peptides to reach systemic tissues and signal through distinct pathways compared to free amino acids.

3.3 mTORC1 Signaling and Protein Synthesis

The central, well-established mechanism of action of leucine — and by extension leucine-containing tripeptides that liberate leucine upon hydrolysis or act intact — is activation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. Recent research has uncovered the mechanisms underlying leucine's anabolic effects on muscle and other tissues, including its ability to stimulate protein synthesis by activating the mTORC1 signaling pathway.

Human and animal studies demonstrate that a physiological increase in plasma leucine stimulates muscle protein synthesis via the mTORC1 pathway by promoting phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor (eIF)4E-binding protein 1 (4E-BP1), as well as the formation of the eIF4G-eIF4E complex that regulates mRNA translation. This leucine-stimulated process involves dissociation of the Sestrin2-GATOR2 complex and increased binding of Rag A/C to mTOR.

Leucine is regarded as an anabolic trigger for the mTORC1 pathway and translation initiation, allowing for the assembly of the structural machinery for protein synthesis at the ribosomal level. Following consumption of dietary protein, the bioavailability of essential amino acids (EAA), and primarily leucine, drives a transient increase in muscle protein synthesis (MPS) with an ensuing refractory period before the next MPS stimulation is possible.

3.4 Metabolic Fate and Key Metabolites

Leucine residues liberated from the tripeptide are subject to a defined catabolic pathway. As a branched-chain amino acid, leucine is transaminated in muscle by branched-chain aminotransferase (BCAT) to α-ketoisocaproate (α-KIC) before decarboxylation to isovaleryl-CoA by the mitochondrial enzyme branched-chain α-ketoacid dehydrogenase (BCKDH), then finally forming acyl-CoA derivatives and entering the citric acid cycle. In the liver, an alternative metabolic fate for leucine has been shown wherein the cytosolic enzyme α-KIC dioxygenase generates β-hydroxy-β-methylbutyrate (HMB) from leucine.

After leucine is metabolized to KIC, KIC is either metabolized into isovaleryl-CoA by BCKDC or into HMB by the enzyme KIC dioxygenase. HMB is itself a recognized anabolic and anti-catabolic compound; HMB stimulates mTORC1 activation in neonatal muscle independent of the leucine-sensing pathway mediated by Sestrin2 and the Rag proteins.

3.5 Effects on Lipid Metabolism and Energy Homeostasis

Research has highlighted leucine's role in lipid metabolism and energy homeostasis in vivo and in vitro by accelerating fatty acid oxidation, lipolysis, and activation of the AMPK–SIRT1–PGC-1α signaling axis, favoring a reduction in adiposity. Leucine has also been shown to benefit lipid metabolism and insulin sensitivity, making it a promising strategy for preventing and treating metabolic diseases, including type 2 diabetes and obesity.

3.6 ACE-Inhibitory Activity of Leucine-Containing Tripeptides

A distinct mechanistic property of certain leucine-containing tripeptide sequences — separate from mTOR signaling — is inhibition of angiotensin-converting enzyme (ACE). ACE-inhibitory peptides exhibit antihypertensive effects by inhibiting ACE activity; the ACE-inhibitory peptide Leu–Leu–Tyr (LLY), isolated from casein hydrolysate, exhibits high ACE-inhibitory activity and stability. The Lineweaver-Burk plot indicated the non-competitive inhibition pattern of LLY, suggesting that it binds to the enzyme at the non-active site.

3.7 Insulin and GLP-1 Secretagogue Activity

Leucine can promote the release of insulin from pancreatic cells, a crucial anabolic signal in skeletal muscle, and enhance the absorption of glucose by skeletal muscle. At the tripeptide level, the tripeptide glycine-glycine-leucine (Diapin) elevated plasma insulin and GLP-1 levels in diabetic mice. Dietary amino acids and peptides can also induce insulin secretion through GLP-1 stimulation mechanisms. These effects at the tripeptide level are, however, largely based on animal or in vitro data as of current evidence.

4. Scientific Evidence by Area of Use

4.1 Skeletal Muscle Protein Synthesis and Anabolism

Evidence from Leucine in Di- and Tripeptide Form vs. Free Leucine

The most directly relevant human clinical evidence for leucine in peptide form — the pharmacological rationale underlying leucine tripeptide supplementation — comes from a 2021 double-blind, randomized, crossover trial published in the Journal of Applied Physiology by Paulussen et al. at the University of Illinois Urbana-Champaign. In a randomized control study of 10 healthy young men, researchers compared how consuming the single amino acid leucine or its two-molecule equivalent, dileucine (Leu-Leu), influenced muscle-building and breakdown, finding that dileucine boosted the metabolic processes driving muscle growth 42% more than free leucine did. Those who consumed dileucine had 42% more synthesis of new muscle proteins than those who ingested only leucine.

The overall findings of this study indicate that dileucine ingestion may be a more effective anabolic trigger for the stimulation of postprandial muscle protein synthesis rates when compared with the ingestion of free leucine alone. A trend was demonstrated for faster time to peak plasma concentrations of dileucine (17 ± 5 min) versus leucine (30 ± 13 min).

Notably, this study involved dileucine (a dipeptide) rather than trileucine, and future work would be required to conceptualize the effectiveness of dileucine versus leucine against the background of coingesting a full complement of essential and nonessential amino acids. Furthermore, the sample was small (n = 10), limiting generalizability. The study also examined only an acute, resting condition in young males.

A subsequent 2025 study (Aguilera et al., published in the Journal of the International Society of Sports Nutrition) tested a dileucine-supplemented essential amino acid formula (DIEAA; 2 g dileucine, 1 g leucine, 9.15 g total EAA) after resistance exercise in young recreationally active adults. Stable isotope-derived rates of mixed muscle protein synthesis demonstrated a trend toward a main effect (p = 0.086) with pairwise comparisons revealing a large effect of DIEAA compared to collagen hydrolysate (dz = 1.47), a medium effect of DIEAA compared to BCAA (dz = 0.81), and a trivial effect of BCAA compared to collagen hydrolysate (dz = 0.002). Dileucine-supplemented EAA and BCAA support greater whole-body anabolism compared with collagen hydrolysate after resistance exercise; exploratory ex vivo experiments reveal a potential anabolic effect of DIEAA in stimulating MPS.

Evidence strength assessment: For leucine in dipeptide or tripeptide form specifically (rather than free leucine), evidence is preliminary. The most directly applicable human RCT (Paulussen et al., 2021) had only 10 participants, was conducted at rest, and tested dileucine, not trileucine. No large-scale, long-term, or exercise-focused trials with isolated trileucine (Leu-Leu-Leu) in humans were identified. The broader mechanistic rationale is well-grounded, but the specific clinical utility of trileucine as a supplement warrants further investigation.

Evidence from Leucine Supplementation in General (Free Leucine)

A large body of research supports the anabolic role of leucine as a free amino acid, forming the mechanistic backdrop for understanding leucine tripeptide effects. A systematic review published in Clinical Nutrition (2023) summarized: muscle protein synthesis and muscle protein breakdown are influenced through dietary protein intake and physical inactivity, which regulate skeletal muscle mass across the lifespan; following consumption of dietary protein, the bioavailability of essential amino acids, and primarily leucine, drives a transient increase in MPS.

Post-endurance exercise, a crossover study in 12 trained men (Rowlands et al., 2015) found that a 33% increase in myofibrillar fractional synthetic rate (FSR) with 5LEU (mean: 0.080%/h) versus a carbohydrate-only control (0.060%/h) represented near-maximal FSR. Tripling the protein-leucine dose negligibly increased FSR (by only 13%, ±12% vs. the lower dose). This suggests a ceiling effect exists for leucine-stimulated MPS at moderate doses.

4.2 Sarcopenia and Age-Related Muscle Loss

In overall terms, published results show that administration of leucine or leucine-enriched proteins (range 1.2–6 g leucine/day) is well-tolerated and significantly improves sarcopenia in elderly individuals, mainly by improving lean muscle-mass content; most such protocols also include vitamin D co-administration. The effect on muscular strength showed mixed results, and the effect on physical performance has seldom been studied; for sarcopenia associated with specific disorders, the most promising effects of leucine supplementation are reported for rehabilitation of post-stroke patients and in those with liver cirrhosis.

A meta-analysis of 17 randomized controlled trials (published in Frontiers in Nutrition, 2022) found: leucine-combined supplementation including vitamin D exhibited a significant benefit for muscle strength and performance, including handgrip strength and gait speed, in older adults.

One trial (Martínez-Arnau et al., 2020) included individuals aged 65 years or older randomly assigned to a 13-week parallel group intervention. Individuals received 6 g of leucine daily or 6 g of lactose daily; leucine administration considerably enhanced walking time, but there was no significant difference in the skeletal muscle mass index or handgrip strength between the two groups. The LACE trial (2022) showed that leucine did not increase the short physical performance battery (SPPB) score in individuals randomly assigned to receive 2.5 g of oral leucine three times daily as opposed to placebo.

Against immobilization-induced muscle loss specifically, a 2025 double-blind RCT (n = 48; 24 young, 24 older adults) published in The American Journal of Clinical Nutrition reported: in young and older adults, MPS rates were approximately 15% and 23% lower in the immobilized compared with non-immobilized leg, with no differences between leucine supplementation compared with placebo treatments. The study design had participants receive 5 g of leucine 3× daily with each main meal during 3 days of unilateral knee immobilization by means of a full leg cast, versus an energy-matched carbohydrate placebo. This finding suggests that free leucine supplementation at this dose is insufficient to attenuate short-term disuse atrophy.

Evidence strength assessment: For leucine (free amino acid) in sarcopenia, evidence is moderate: improvements in lean mass are more consistently reported than improvements in strength or function, results are heterogeneous across trials, and co-supplementation with vitamin D appears to be a modifying factor. No human trials specifically on trileucine in sarcopenia populations were identified.

4.3 Antihypertensive Effects (ACE Inhibition)

Leucine-containing tripeptides with sequences such as Leu-Leu-Tyr (LLY) from casein hydrolysate have been investigated for angiotensin-converting enzyme (ACE) inhibitory activity. Systematic investigations were conducted on the interaction between ACE and LLY through various approaches; the Lineweaver-Burk plot indicated a non-competitive inhibition pattern, suggesting binding to the non-active site; multispectral experiments and atomic force microscopy were also conducted to elucidate the mechanism of peptide activity.

During the past three decades, food protein-derived antihypertensive peptides have gained substantial interest as a promising alternative to antihypertensive drugs. Compared with chemically synthesized ACE inhibitors, ACE-inhibitory peptides identified in food proteins have some advantages, as they are economical, can be obtained from various sources, are considered safe, and are more easily accepted by consumers.

However, several challenges must be faced before novel ACE-inhibitory peptides can be used by the food or pharmaceutical industry, regarding their bioavailability, antihypertensive effect, in vivo safety, and stability in different processing conditions; the amino acid sequence, especially the C-terminal tripeptide, plays a crucial role in the physiological functions of ACE-inhibitory peptides.

Evidence strength assessment: ACE-inhibitory activity of leucine-containing tripeptides (e.g., LLY) is supported by in vitro and animal model data. Robust, large-scale human trials specifically testing isolated Leu-Leu-Leu or LLY for blood pressure outcomes were not identified. Evidence is currently preliminary and mostly preclinical.

4.4 Glucose Metabolism and Diabetes-Related Endpoints

Peptides produced from proline, glycine, and leucine, especially Leu-Gly and carnosine dipeptides, caused a significant prevention of blood glucose elevation in mice at risk of diabetes. The tripeptide Gly-Gly-Leu (Diapin) elevated plasma insulin and GLP-1 levels in diabetic mice. It activates the mechanistic target of rapamycin and cAMP pathways, leading to increased protein synthesis, specifically insulin, by β-cells as an insulin production stimulator, and prevents mitochondrial gene mutations.

Leucine has been shown to benefit lipid metabolism and insulin sensitivity, making it a promising strategy for preventing and treating metabolic diseases, including type 2 diabetes and obesity.

Evidence strength assessment: Effects on glucose homeostasis via leucine-containing tripeptides are preliminary, based primarily on animal/in vitro models. No dedicated human clinical trials on trileucine specifically for glycemic outcomes were identified.

4.5 Immune Function and T-Cell Activation

In connection with the increasing interest in metabolic regulation of immune response, leucine has been described as an important essential amino acid and a nutrient signal that activates mTORC1, which is a critical regulator of T cell proliferation, differentiation, and function. The downstream leucine metabolite α-KIC and HMB have also demonstrated immunomodulatory effects in preclinical models. Evidence for leucine tripeptide in particular driving immune outcomes in humans is not established in clinical studies.

Evidence strength assessment: Preliminary; primarily mechanistic/preclinical data.

5. Body Systems and Health Areas Associated with Leucine Tripeptide

• Musculoskeletal system: Primary area of research. Leucine and leucine-containing peptides are linked to skeletal muscle protein synthesis, preservation of muscle mass in aging (sarcopenia), and exercise recovery. Leucine regulates growth and development through various mechanisms, including protein synthesis, energy metabolism, and immune function.
• Cardiovascular system: Leucine-containing tripeptide sequences (e.g., LLY from casein) have demonstrated in vitro ACE-inhibitory properties relevant to blood pressure regulation.
• Endocrine/metabolic system: Leucine and leucine-derived tripeptides intersect with insulin secretion, GLP-1 release, and glucose metabolism, with relevance to type 2 diabetes and obesity. Leucine can promote the release of insulin from pancreatic cells and enhance glucose absorption by skeletal muscle.
• Immune system: Leucine has been described as a nutrient signal that activates mTORC1, a critical regulator of T cell proliferation, differentiation, and function.
• Hepatic system: The most promising effects of leucine supplementation for disorder-associated sarcopenia include those in patients with liver cirrhosis.

6. Dosage Forms and Dosages Reported in Studies

Dosages reported in peer-reviewed research vary by form (free leucine versus peptide-bound leucine) and population:

• Free leucine, sarcopenia trials: Administration of leucine or leucine-enriched proteins in a range of 1.2 to 6 g leucine/day has been well-tolerated in elderly individuals.
• Free leucine, immobilization trial: 5 g of leucine 3× daily with each main meal (15 g/day total), administered during 3 days of unilateral knee immobilization.
• Free leucine, LACE trial: 2.5 g of oral leucine three times daily (7.5 g/day total) as opposed to placebo.
• Free leucine, 13-week trial (Martínez-Arnau et al.): 6 g of leucine daily for 13 weeks in individuals aged 65 years or older.
• Dileucine (Leu-Leu), human RCT (Paulussen et al., 2021): The study investigated an acute, bolus dose of dileucine at an equimolar leucine-equivalent amount; exact dose in milligrams was not directly specified in the available abstract data, but the dose was matched for total leucine content against the free leucine comparator condition.
• Dileucine-supplemented EAA formula (DIEAA): The DIEAA formula used in one study contained 2 g dileucine, 1 g leucine, and 9.15 g total EAA.
• Protein-leucine blend, endurance exercise trial: In a crossover design, 12 trained men consumed either 70 g protein/15 g leucine/180 g carbohydrate/30 g fat (15LEU) or 23 g protein/5 g leucine/180 g carbohydrate/30 g fat (5LEU), or a carbohydrate-only control, in four servings during 90 minutes of recovery from high-intensity cycling.

No standardized, pharmacopoeia-recognized dosage for trileucine (Leu-Leu-Leu) as an isolated ingredient has been established. Dose findings for free leucine cannot be extrapolated directly to the tripeptide form without dedicated dose-finding clinical trials.

7. Safety Considerations and Known Interactions

7.1 General Tolerability

Toxicity from orally administered leucine is extremely low; ingestion of even large quantities produces only minor gastrointestinal symptoms such as nausea and/or vomiting. Administration of leucine or leucine-enriched proteins in a range of 1.2 to 6 g leucine/day is well-tolerated in elderly individuals.

7.2 Contraindications: Inborn Errors of Amino Acid Metabolism

The most significant safety concern specific to leucine-containing compounds — including leucine tripeptide — relates to rare hereditary metabolic disorders. Hypersensitivity to branched-chain amino acids, anuria, and inborn errors of amino acid metabolism, especially those involving branched-chain amino acid metabolism such as maple syrup urine disease (MSUD) and isovaleric acidemia, are contraindications to BCAA supplementation.

Maple syrup urine disease (MSUD) is a rare genetic disorder characterized by deficiency of an enzyme complex (branched-chain alpha-keto acid dehydrogenase) required to break down leucine, isoleucine, and valine; the result is that all three BCAAs, along with a number of their toxic byproducts, accumulate abnormally. The toxicity results from the damaging effects of leucine on the brain accompanied by severe ketoacidosis caused by accumulation of the three branched-chain ketoacids. MSUD is an absolute contraindication to leucine tripeptide supplementation.

7.3 Potential Competitive Imbalances with Other BCAAs

High-dose leucine or leucine-peptide supplementation in isolation raises a physiological concern: leucine shares transport systems with isoleucine and valine. In MSUD, leucine accumulation and its metabolites cause brain toxicity; valine and isoleucine supplements are necessary to promote anabolism and enable prompt reduction of plasma leucine. In the context of non-MSUD individuals taking isolated leucine supplements, some researchers have noted the theoretical risk that high-dose leucine may competitively reduce plasma concentrations of isoleucine and valine, though the clinical significance of this at typical supplement doses remains to be definitively established in large human trials.

7.4 Interactions with Medications

A food-drug interaction between milk (a source of leucine-containing peptides) and the PEPT1 substrate oseltamivir has been reported; in vitro investigations also suggest that quinolone antibiotics such as moxifloxacin may interfere with the absorption of PEPT1 substrates. Because leucine tripeptide is itself a PEPT1 substrate, co-administration with drugs that compete for PEPT1-mediated transport could theoretically reduce the absorption of either the peptide or the co-administered drug. The clinical significance of these interactions in human supplementation contexts has not been fully characterized.

7.5 Considerations in Specific Populations

While emerging evidence indicates that epigenetic mechanisms may mediate leucine's effects on growth and development, more research is needed to elucidate its mechanisms of action fully. Leucine supplementation may cause digestive issues or interact with certain medications, and more study is required to determine definitively optimal dosages.

8. Limitations and Research Gaps

The current scientific literature on leucine tripeptide (Leu-Leu-Leu specifically) as an isolated dietary supplement ingredient is sparse and largely preliminary. Most human clinical evidence bearing on the topic examines free L-leucine, leucine-enriched protein hydrolysates, or the related dipeptide dileucine (Leu-Leu). Key research gaps include:

• No large-scale, long-term human RCTs using isolated trileucine (Leu-Leu-Leu) as a supplement have been identified.
• The dose-response relationship for trileucine in humans has not been established.
• Comparative studies of trileucine versus dileucine versus free leucine in the same human study design are lacking.
• The bioavailability of intact trileucine versus its hydrolytic products in vivo in humans has not been characterized in detail.
• Long-term safety data for supplemental trileucine are absent.
• Further placebo-controlled trials will be necessary to determine the effects of leucine preparations and to evaluate outcomes with the criteria recommended by official Working Groups, thereby limiting the variability of methodological issues across studies.

References

• PubChem — Trileucine (Leu-Leu-Leu), CID 82546
• Britannica — Leucine: Branched-Chain, Protein Synthesis, Metabolism
• Technology Networks — Essential Amino Acids: Chart, Abbreviations and Structure
• Frontiers in Physiology — Research progress in the role and mechanism of Leucine in regulating animal growth and development (2023)
• Nutrients (MDPI) — Leucine Supplementation: A Novel Strategy for Modulating Lipid Metabolism and Energy Homeostasis (2020)
• Journal of Applied Physiology — Dileucine ingestion is more effective than leucine in stimulating muscle protein turnover in young males: a double blind randomized controlled trial (2021)
• Journal of the International Society of Sports Nutrition — Dileucine-supplemented essential amino acids support whole-body anabolism after resistance exercise (2025)
• Clinical Nutrition — A focus on leucine in the nutritional regulation of human skeletal muscle metabolism in ageing, exercise and unloading states (2023)
• PubMed/AJCN — Leucine supplementation does not attenuate the decline in daily muscle protein synthesis rates or preserve leg muscle mass during leg immobilization (2025)
• PubMed — Protein-leucine fed dose effects on muscle protein synthesis after endurance exercise (2014)
• PMC — Beneficial Effects of Leucine Supplementation on Criteria for Sarcopenia: A Systematic Review (2019)
• PMC — Effects of Leucine Supplementation in Older Adults with Sarcopenia: A Meta-Analysis (2025)
• PubMed — The Effect of Leucine Supplementation on Sarcopenia-Related Measures in Older Adults: A Systematic Review and Meta-Analysis of 17 Randomized Controlled Trials (2022)
• PMC — Investigation of the Interaction Between Angiotensin-Converting Enzyme (ACE) and ACE-Inhibitory Tripeptide from Casein (2024)
• Journal of Diabetes Investigation — Leucine–glycine and carnosine dipeptides prevent diabetes induced by multiple low‐doses of streptozotocin (2019)
• Food Chemistry — Intestinal epithelial transport of bioactive di/tripeptides through PepT1: Molecular mechanism and influencing factors (2025)
• PMC — Transcriptional and functional regulation of the intestinal peptide transporter PEPT1 (2014)
• Molecular Pharmaceutics — Targeted Disruption of Peptide Transporter Pept1 Gene in Mice Significantly Reduces Dipeptide Absorption (2008)
• Journal of Clinical Investigation — PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin (2001)
• Solvo Biotechnology — PEPT1 Transporter Overview
• PMC — Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond (2016)
• PMC — Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism (2013)
• PMC — Differential regulation of mTORC1 activation by leucine and β-hydroxy-β-methylbutyrate in skeletal muscle of neonatal pigs (2020)
• PMC — Utilization of HMB, Leucine, Glutamine and Arginine Supplementation in Nutritional Management of Sarcopenia (2020)
• ClinicalTrials.gov — Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia
• NORD — Maple Syrup Urine Disease
• PMC — Alternative sources of valine and isoleucine for prompt reduction of plasma leucine in maple syrup urine disease (2022)
• PMC — Two Novel Antihypertensive Peptides Identified in Millet Bran Glutelin-2 Hydrolysates (2022)
• PubMed — Leucine content of dietary proteins is a determinant of postprandial skeletal muscle protein synthesis in adult rats (2012)
• PMC — The Effect of Leucine-Enriched β-Lactoglobulin Versus an Isonitrogenous Whey Protein Isolate on Skeletal Muscle Protein Anabolism in Young Healthy Males (2025)